Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30410721 | 0.86 | CYP3A4 (0.52) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL180797 | 0.86 | CYP3A4 (0.65) | CYP3A4SMN1; SMN2MEN1KMT2ACES1 | |
| SCHEMBL91278 | 0.85 | TP53 (0.55) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL15054592 | 0.85 | TP53 (0.55) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL362241 | 0.83 | ALDH1A1 (0.56) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL1928079 | 0.83 | ALDH1A1 (0.56) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL16951368 | 0.81 | CYP3A4 (0.46) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL6582839 | 0.80 | CYP3A4 (0.46) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL11810790 | 0.79 | CYP3A4 (0.49) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 | |
| SCHEMBL583571 | 0.79 | MEN1 (0.55) | CYP3A4SMN1; SMN2MEN1KMT2AACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | LIPOSCIENCES, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2017-08-10 | — | — | US | disclosed |
| EP-3067359-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Petersen, Scott G. (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| EP-2346883-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | Traversa Therapeutics, Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010039543-A2 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | TRAVERSA THERAPEUTICS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329775-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | CYP3A4 4878/4885SMN1; SMN2 567/4885MEN1 3597/4885 |
| US-20110294869-A1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | CYP3A4 4878/4885SMN1; SMN2 567/4885MEN1 3597/4885 |
| US-10022454-B2 | Functionalized phosphorodiamites for therapeutic oligonucleotide synthesis | NCL, PHOSPHO1, POLN | CYP3A4 4881/4885SMN1; SMN2 543/4885MEN1 3892/4885 |
| US-20170224832-A9 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | POLN, SARNP, NCL | CYP3A4 4878/4885SMN1; SMN2 567/4885MEN1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.